Is nonapeptide-1 FDA-approved, and what does the research show?

What is nonapeptide-1?

Nonapeptide-1 is a synthetic peptide ¹, a short chain of amino acids made in a laboratory; the name means a peptide of nine of them. Cosmetic makers buy it from Clariant as Melanostatine 5 BG, a mixture listed as water, butylene glycol, dextran and nonapeptide-1 ². The maker calls it a "biomimetic peptide antagonist of α-MSH" ². That means a laboratory copy of a natural signal, one that blocks a hormone's receptor rather than switching it on.

α-MSH, alpha-melanocyte-stimulating hormone, is the messenger that tells melanocytes, the skin's pigment cells, to make melanin after sun exposure ³. The 2022 cell study that used nonapeptide-1 calls it "a novel peptide" that "competes with α-MSH and binds to MC1R," the receptor for that hormone ³.

Is nonapeptide-1 FDA-approved?

No. FDA approves no cosmetic ingredient before sale except color additives ⁴. FDA's page on cosmetics, current as of November 18, 2025, says that "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives" ⁴. Nonapeptide-1 is not FDA-approved as a drug either: Drugs@FDA lists no approved nonapeptide-1 or Melanostatine product as of November 9, 2026 ⁵.

Under the law, the company that makes or sells a cosmetic is answerable for its safety and must hold records that substantiate it ⁴,⁷. The Modernization of Cosmetics Regulation Act of 2022, known as MoCRA, gave FDA the power to order a recall, on a condition: a "reasonable probability that a cosmetic is adulterated or misbranded" and that it "will cause serious adverse health consequences or death" ⁷. Then "FDA has the authority to order a mandatory recall if the responsible person refuses to do so voluntarily" ⁷.

Whether a product is a cosmetic or a drug turns on its intended use ⁸. FDA reads that use from the product's claims, its reputation and its ingredients ⁸. FDA's page on that distinction is current as of September 11, 2024 ⁸. Among the claims that make a product a drug, it lists "claims that products will ... increase or decrease the production of melanin (pigment) in the skin" ⁸. The page describes the claim, not any ingredient, and it does not name nonapeptide-1 ⁸.

The ingredient is studied for melanin production, so FDA's pages on skin-lightening products are the nearest it has written. Its consumer page, current as of May 11, 2026, says these products "are marketed as treatments for uneven skin tone, acne, age spots, freckles, and wrinkles" ⁹. A second page, current as of August 24, 2026, speaks of over-the-counter (OTC) products, the kind sold without a prescription: "there are no FDA-approved or legally marketed OTC skin lightening products" ¹⁰. Neither page names nonapeptide-1 ⁹,¹⁰.

See the FDA status of every peptide, updated weekly.

How does nonapeptide-1 work?

The proposed mechanism is competition at a receptor. After ultraviolet light, skin cells release α-MSH, which acts on MC1R, the melanocortin 1 receptor on pigment cells ³. That pathway drives the enzymes that build melanin ³. A peptide that competes with α-MSH for MC1R would leave the hormone less room to act, the study's authors propose ³.

Shown in cells: in a 2022 study of tea polyphenols, nonapeptide-1 acetate was the comparison treatment ³. Human melanocytes exposed to it made less melanin and showed less activity of tyrosinase, the pigment enzyme ³. They also expressed less MC1R, tyrosinase, TRP1, TRP2 and MITF, the proteins of the pigment pathway ³. It did not lower the output of α-MSH from keratinocytes, the skin's surface cells, which the tea polyphenols did ³.

Peptides that block the α-MSH receptor were reported in 1994 ¹¹. A screen of about 40 percent of a 31,360-peptide library built on part of the hormone's sequence found several that blocked the receptor rather than activating it ¹¹. No source opened states nonapeptide-1's sequence or whether it came from that screen.

What does the research show?

No published human study of nonapeptide-1 on its own was found. A PubMed search on November 10, 2026 returned four papers naming it, one of which involved people ³,⁶,¹². A second trial in people was published in 2025 ¹.

Studied in people, as part of a blend: a randomized, double-blind pilot trial in Kolkata, India, enrolled 46 adults with melasma, 42 of them women ⁶. Double-blind means neither patients nor assessors knew who used which.

All used a triple-combination cream of tretinoin, a corticosteroid and hydroquinone for eight weeks first ⁶. Then the blend group (23 randomized) applied a blend of phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen twice a day for 16 weeks ⁶. The sunscreen group (23 randomized) applied sunscreen alone ⁶. In the blend group 17 finished the whole study; on sunscreen 15 completed the 16 weeks (Table 7 shows 14 at the last visits) and 14 the whole study ⁶. Most of the rest were lost to follow-up ⁶.

On the clinicians' severity scale, one person in the blend group improved, none on sunscreen did, and 4 and 5 worsened ⁶. The groups did not differ (P = 0.55, a difference chance could explain) ⁶. The melanin readings at the end of treatment did not differ significantly either (P = 0.59) ⁶.

The Melasma Area and Severity Index is the clinicians' score of how much skin is affected and how dark ⁶. It fell from 9.9 to 7.8 in the blend group over the whole study ⁶. On sunscreen it rose from 9.0 to 9.9, a comparison the paper gives no P value for ⁶. Most of the fall came in the first eight weeks, before the blend ⁶. From the start of the blend phase the score rose from 7.3 to 7.8 in the blend group and from 5.5 to 9.9 on sunscreen ⁶.

The authors call the blend "more effective," and write that their small sample and short follow-up "led to results that did not reach statistical significance" ⁶. The study was supported by Palsons Derma, an Indian company, and the paper does not state how much nonapeptide-1 the blend contained ⁶. This is a study of the blend; it cannot say what nonapeptide-1 did on its own.

The second trial, a randomized one in Hangzhou, China, enrolled 62 women with melasma ¹. All took tranexamic acid by mouth for 12 weeks ¹. Thirty-one also applied hydroquinone cream, and 31 a skin-lightening cosmetic containing Cordyceps extract, arbutin, glabridin and nonapeptide-1 at 3 percent ¹.

Twenty-nine and 30 finished; the severity index and the melanin readings fell in both groups, and the groups did not differ significantly ¹. The study was supported by the Hangzhou biomedical and health industry development support project ¹. It compared two treatments of several ingredients each, so it too cannot say what nonapeptide-1 did on its own.

A 2024 laboratory study used nonapeptide-1 bound to silica nanoparticles carrying a green-tea compound ¹². It is a study of that carrier, not of the peptide, and its abstract reports work in cells and in living tissue (species not stated in the abstract) ¹². No study of how much nonapeptide-1 passes through skin, and no long-term human study, was found.

What are the side effects?

The only human safety data come from the two melasma trials, in which safety was one of the stated aims ⁶,¹. In the pilot, during the 16 weeks on the blend, one of 17 people reported itching ⁶. Among the 15 people on sunscreen alone, four events were reported: itching, allergic contact dermatitis, burning and redness ⁶. The authors describe the blend's adverse effects as "minimal" ⁶.

In the 2025 trial, adverse reactions occurred in 4 people (13.8 percent) on hydroquinone cream and in 1 person (3.3 percent) on the cosmetic containing nonapeptide-1, who had facial itching ¹. No safety assessment of nonapeptide-1 by the Cosmetic Ingredient Review, the industry-funded panel that assesses cosmetic ingredients, appears in its list of reviewed ingredients as of November 10, 2026.

In sport

Nonapeptide-1 is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency, under that name or as Melanostatine ¹³.

What JumpstartMD offers

JumpstartMD does not prescribe nonapeptide-1. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.